Iron Deposition on SWI-Filtered Phase in the Subcortical Deep Gray Matter of Patients with Clinically Isolated Syndrome May Precede Structure-Specific Atrophy

References

1. 1.↵
   1. Pirko I,
   2. Lucchinetti CF,
   3. Sriram S,
   4. et al

   . Gray matter involvement in multiple sclerosis. Neurology 2007;68:634–42

   Abstract/FREE Full Text
2. 2.↵
   1. Fisher E,
   2. Lee JC,
   3. Nakamura K,
   4. et al

   . Gray matter atrophy in multiple sclerosis: a longitudinal study. Ann Neurol 2008;64:255–65

   CrossRefPubMedWeb of Science
3. 3.↵
   1. Audoin B,
   2. Ibarrola D,
   3. Malikova I,
   4. et al

   . Onset and underpinnings of white matter atrophy at the very early stage of multiple sclerosis–a two-year longitudinal MRI/MRSI study of corpus callosum. Mult Scler 2007;13:41–51

   Abstract/FREE Full Text
4. 4.↵
   1. Audoin B,
   2. Zaaraoui W,
   3. Reuter F,
   4. et al

   . Atrophy mainly affects the limbic system and the deep grey matter at the first stage of multiple sclerosis. J Neurol Neurosurg Psychiatry 2010;81:690–95

   Abstract/FREE Full Text
5. 5.↵
   1. Calabrese M,
   2. Atzori M,
   3. Bernardi V,
   4. et al

   . Cortical atrophy is relevant in multiple sclerosis at clinical onset. J Neurol 2007;254:1212–20

   CrossRefPubMedWeb of Science
6. 6.↵
   1. Henry RG,
   2. Shieh M,
   3. Amirbekian B,
   4. et al

   . Connecting white matter injury and thalamic atrophy in clinically isolated syndromes. J Neurol Sci 2009;282:61–66

   CrossRefPubMedWeb of Science
7. 7.↵
   1. Henry RG,
   2. Shieh M,
   3. Okuda DT,
   4. et al

   . Regional grey matter atrophy in clinically isolated syndromes at presentation. J Neurol Neurosurg Psychiatry 2008;79:1236–44

   Abstract/FREE Full Text
8. 8.↵
   1. Ramasamy DP,
   2. Benedict RH,
   3. Cox JL,
   4. et al

   . Extent of cerebellum, subcortical and cortical atrophy in patients with MS: a case-control study. J Neurol Sci 2009;282:47–54

   CrossRefPubMedWeb of Science
9. 9.↵
   1. Roosendaal SD,
   2. Bendfeldt K,
   3. Vrenken H,
   4. et al

   . Grey matter volume in a large cohort of MS patients: relation to MRI parameters and disability. Mult Scler 2011;17:1098–106

   Abstract/FREE Full Text
10. 10.↵
    1. Fisniku LK,
    2. Chard DT,
    3. Jackson JS,
    4. et al

    . Gray matter atrophy is related to long-term disability in multiple sclerosis. Ann Neurol 2008;64:247–54

    CrossRefPubMedWeb of Science
11. 11.↵
    1. Calabrese M,
    2. Rinaldi F,
    3. Mattisi I,
    4. et al

    . The predictive value of gray matter atrophy in clinically isolated syndromes. Neurology 2011;77:257–63

    Abstract/FREE Full Text
12. 12.↵
    1. Dalton CM,
    2. Chard DT,
    3. Davies GR,
    4. et al

    . Early development of multiple sclerosis is associated with progressive grey matter atrophy in patients presenting with clinically isolated syndromes. Brain 2004;127:1101–07

    Abstract/FREE Full Text
13. 13.↵
    1. Raz E,
    2. Cercignani M,
    3. Sbardella E,
    4. et al

    . Gray- and white-matter changes 1 year after first clinical episode of multiple sclerosis: MR imaging. Radiology 2010;257:448–54

    CrossRefPubMedWeb of Science
14. 14.↵
    1. Bakshi R,
    2. Benedict RHB,
    3. Bermel RA,
    4. et al

    . T2 hypointensity in the deep gray matter of patients with multiple sclerosis: a quantitative magnetic resonance imaging study. Arch Neurol 2002;59:62

    CrossRefPubMedWeb of Science
15. 15.↵
    1. Brass SD,
    2. Benedict RHB,
    3. Weinstock-Guttman B,
    4. et al

    . Cognitive impairment is associated with subcortical magnetic resonance imaging grey matter T2 hypointensity in multiple sclerosis. Mult Scler 2006;12:437

    Abstract/FREE Full Text
16. 16.↵
    1. Tjoa CW,
    2. Benedict RH,
    3. Weinstock-Guttman B,
    4. et al

    . MRI T2 hypointensity of the dentate nucleus is related to ambulatory impairment in multiple sclerosis. J Neurol Sci 2005;234:17–24

    CrossRefPubMedWeb of Science
17. 17.↵
    1. Burgetova A,
    2. Seidl Z,
    3. Krasensky J,
    4. et al

    . Multiple sclerosis and the accumulation of iron in the basal ganglia: quantitative assessment of brain iron using MRI t(2) relaxometry. Eur Neurol 2010;63:136–43

    CrossRefPubMed
18. 18.↵
    1. Khalil M,
    2. Enzinger C,
    3. Langkammer C,
    4. et al

    . Quantitative assessment of brain iron by R(2)* relaxometry in patients with clinically isolated syndrome and relapsing-remitting multiple sclerosis. Mult Scler 2009;15:1048–54

    Abstract/FREE Full Text
19. 19.↵
    1. Khalil M,
    2. Langkammer C,
    3. Ropele S,
    4. et al

    . Determinants of brain iron in multiple sclerosis: A quantitative 3T MRI study. Neurology 2011;77:1691–97

    Abstract/FREE Full Text
20. 20.↵
    1. Ge Y,
    2. Jensen JH,
    3. Lu H,
    4. et al

    . Quantitative assessment of iron accumulation in the deep gray matter of multiple sclerosis by magnetic field correlation imaging. AJNR Am J Neuroradiol 2007;28:1639

    Abstract/FREE Full Text
21. 21.↵
    1. Eissa A,
    2. Lebel RM,
    3. Korzan JR,
    4. et al

    . Detecting lesions in multiple sclerosis at 4.7 Tesla using phase susceptibility-weighting and T2-weighting. J Magn Reson Imaging 2009;30:737–42

    CrossRefPubMed
22. 22.↵
    1. Haacke EM,
    2. Makki M,
    3. Ge Y,
    4. et al

    . Characterizing iron deposition in multiple sclerosis lesions using susceptibility weighted imaging. J Magn Reson Imaging 2009;29:537–44

    CrossRefPubMed
23. 23.↵
    1. Zivadinov R,
    2. Heininen-Brown M,
    3. Schirda C,
    4. et al

    . Abnormal subcortical deep-gray matter susceptibility-weighted imaging filtered phase measurements in patients with multiple sclerosis. A case-control study. Neuroimage 2012;59:331–39

    CrossRefPubMedWeb of Science
24. 24.↵
    1. Craelius W,
    2. Migdal MW,
    3. Luessenhop CP,
    4. et al

    . Iron deposits surrounding multiple sclerosis plaques. Arch Pathol Lab Med 1982;106:397–99

    PubMedWeb of Science
25. 25.↵
    1. LeVine SM.

    . Iron deposits in multiple sclerosis and Alzheimer's disease brains. Brain Res 1997;760:298–303

    CrossRefPubMedWeb of Science
26. 26.↵
    1. Fenton H.J.H

    . Oxidation of tartaric acid in presence of iron. J Chem Soc 1894;65:899–903

    CrossRef
27. 27.↵
    1. Khalil M,
    2. Teunissen C,
    3. Langkammer C

    . Iron and neurodegeneration in multiple sclerosis. Mult Scler Int 2011:606807
28. 28.↵
    1. Miller D,
    2. Barkhof F,
    3. Montalban X,
    4. et al

    . Clinically isolated syndromes suggestive of multiple sclerosis, part I: natural history, pathogenesis, diagnosis, and prognosis. Lancet Neurol 2005;4:281–88

    CrossRefPubMedWeb of Science
29. 29.↵
    1. Ceccarelli A,
    2. Rocca MA,
    3. Neema M,
    4. et al

    . Deep gray matter T2 hypointensity is present in patients with clinically isolated syndromes suggestive of multiple sclerosis. Mult Scler 2010;16:39–44

    Abstract/FREE Full Text
30. 30.↵
    1. Neema M,
    2. Arora A,
    3. Healy BC,
    4. et al

    . Deep gray matter involvement on brain MRI scans is associated with clinical progression in multiple sclerosis. J Neuroimaging 2009;19:3–8

    CrossRefPubMedWeb of Science
31. 31.↵
    1. Haacke EM,
    2. Mittal S,
    3. Wu Z,
    4. et al

    . Susceptibility-weighted imaging: technical aspects and clinical applications, part 1. AJNR Am J Neuroradiol 2009;30:19

    Abstract/FREE Full Text
32. 32.↵
    1. Polman CH,
    2. Reingold SC,
    3. Banwell B,
    4. et al

    . Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 2011;69:292–302

    CrossRefPubMedWeb of Science
33. 33.↵
    1. Kurtzke JF.

    . Rating neurologic impairment in multiple sclerosis: an Expanded Disability Status Scale (EDSS). Neurology 1983;33:1444–52

    Abstract/FREE Full Text
34. 34.↵
    1. Patenaude B,
    2. Smith SM,
    3. Kennedy DN,
    4. et al

    . A Bayesian model of shape and appearance for subcortical brain segmentation. Neuroimage 2011;56:907–22

    CrossRefPubMedWeb of Science
35. 35.↵
    1. Batista S,
    2. Zivadinov R,
    3. Hoogs M,
    4. et al

    . Basal ganglia, thalamus and neocortical atrophy predicting slowed cognitive processing in multiple sclerosis. J Neurol 2012;259:139–46

    CrossRefPubMedWeb of Science
36. 36.↵
    1. Yeh EA,
    2. Weinstock-Guttman B,
    3. Ramanathan M,
    4. et al

    . Magnetic resonance imaging characteristics of children and adults with paediatric-onset multiple sclerosis. Brain 2009;132:3392–400

    Abstract/FREE Full Text
37. 37.↵
    1. Zivadinov R,
    2. Weinstock-Guttman B,
    3. Benedict R,
    4. et al

    . Preservation of gray matter volume in multiple sclerosis patients with the Met allele of the rs6265 (Val66Met) SNP of brain-derived neurotrophic factor. Hum Mol Genet 2007;16:2659–68

    Abstract/FREE Full Text
38. 38.↵
    1. Zivadinov R,
    2. Rudick RA,
    3. De Masi R,
    4. et al

    . Effects of IV methylprednisolone on brain atrophy in relapsing-remitting MS. Neurology 2001;57:1239–47

    Abstract/FREE Full Text
39. 39.↵
    1. Bakshi R,
    2. Shaikh ZA,
    3. Janardhan V

    . MRI T2 shortening (“black T2”) in multiple sclerosis: frequency, location, and clinical correlation. Neuroreport 2000;11:15–21

    CrossRefPubMedWeb of Science
40. 40.↵
    1. Hammond KE,
    2. Metcalf M,
    3. Carvajal L,
    4. et al

    . Quantitative in vivo magnetic resonance imaging of multiple sclerosis at 7 Tesla with sensitivity to iron. Ann Neurol 2008;64:707–13

    CrossRefPubMedWeb of Science
41. 41.↵
    1. Drayer B,
    2. Burger P,
    3. Darwin R,
    4. et al

    . MRI of brain iron. AJR Am J Roentgenol 1986;147:103–10

    PubMedWeb of Science
42. 42.↵
    1. Bakshi R,
    2. Dmochowski J,
    3. Shaikh ZA,
    4. et al

    . Gray matter T2 hypointensity is related to plaques and atrophy in the brains of multiple sclerosis patients. J Neurol Sci 2001;185:19–26

    CrossRefPubMedWeb of Science
43. 43.↵
    1. Bermel RA,
    2. Puli SR,
    3. Rudick RA,
    4. et al

    . Prediction of longitudinal brain atrophy in multiple sclerosis by gray matter magnetic resonance imaging T2 hypointensity. Arch Neurol 2005;62:1371–76

    CrossRefPubMedWeb of Science
44. 44.↵
    1. Ceccarelli A,
    2. Filippi M,
    3. Neema M,
    4. et al

    . T2 hypointensity in the deep gray matter of patients with benign multiple sclerosis. Mult Scler 2009;15:678–86

    Abstract/FREE Full Text
45. 45.↵
    1. Ceccarelli A,
    2. Rocca MA,
    3. Perego E,
    4. et al

    . Deep grey matter T2 hypo-intensity in patients with paediatric multiple sclerosis. Mult Scler 2011;17:702–07

    Abstract/FREE Full Text
46. 46.↵
    1. Hopp K,
    2. Popescu BF,
    3. McCrea RP,
    4. et al

    . Brain iron detected by SWI high pass filtered phase calibrated with synchrotron X-ray fluorescence. J Magn Reson Iimaging 2010;31:1346–54

    CrossRef
47. 47.↵
    1. Haacke EM,
    2. Xu Y,
    3. Cheng YC,
    4. et al

    . Susceptibility weighted imaging (SWI). Magn Reson Med 2004;52:612–18

    CrossRefPubMedWeb of Science
48. 48.↵
    1. Stankiewicz J,
    2. Panter SS,
    3. Neema M,
    4. et al

    . Iron in chronic brain disorders: imaging and neurotherapeutic implications. Neurotherapeutics 2007;4:371–86

    CrossRefPubMedWeb of Science
49. 49.↵
    1. Snyder AM,
    2. Connor JR.

    . Iron, the substantia nigra and related neurological disorders. Biochim Biophys Acta 2009;1790:606–14

    CrossRefPubMed
50. 50.↵
    1. Haacke EM,
    2. Garbern J,
    3. Miao Y,
    4. et al

    . Iron stores and cerebral veins in MS studied by susceptibility weighted imaging. Int Angiol 2010;29:149–57

    PubMedWeb of Science
51. 51.↵
    1. Zivadinov R,
    2. Weinstock-Guttman B,
    3. Pirko I.

    . Iron deposition and inflammation in multiple sclerosis. Which one comes first? BMC Neurosci 2011;12:60

    CrossRefPubMed
52. 52.↵
    1. Williams R,
    2. Rohr AM,
    3. Wang WT,
    4. et al

    . Iron deposition is independent of cellular inflammation in a cerebral model of multiple sclerosis. BMC Neurosci 2011;12:59

    CrossRefPubMed
53. 53.↵
    1. Schweser F,
    2. Deistung A,
    3. Lehr BW,
    4. et al

    . Quantitative imaging of intrinsic magnetic tissue properties using MRI signal phase: An approach to in vivo brain iron metabolism? Neuroimage 2011;54:2789–807

    CrossRefPubMedWeb of Science
54. 54.↵
    1. Kappos L,
    2. Freedman MS,
    3. Polman CH,
    4. et al

    . Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial. Lancet Neurol 2009;8:987–97

    CrossRefPubMedWeb of Science